IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?

References

• Nowell PC. Phytohemagglutinin: an initiator of mitosis in cultures of normal human leukocytes. Cancer Res 1960; 20:462-6; PMID:14427849
   PubMed Web of Science ®Google Scholar
• Kasakura S, Lowenstein L. A factor stimulating DNA synthesis derived from the medium of leukocyte cultures. Nature 1965; 208:794-5; PMID:5868897; http://dx.doi.org/10.1038/208794a0
   PubMed Web of Science ®Google Scholar
• Gordon J, MacLean LD. A lymphocyte-stimulating factor produced in vitro. Nature 1965; 208:795-6; PMID:4223737; http://dx.doi.org/10.1038/208795a0
   PubMed Web of Science ®Google Scholar
• Gillis S, Smith KA. Long term culture of tumour-specific cytotoxic T cells. Nature 1977; 268:154-6; PMID:145543; http://dx.doi.org/10.1038/268154a0
   PubMed Web of Science ®Google Scholar
• Gillis S, Ferm MM, Ou W, Smith KA. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 1978; 120:2027-32; PMID:307029
   PubMed Web of Science ®Google Scholar
• Gery I, Gershon RK, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. I. The responding cell. J Exp Med 1972; 136:128-42; PMID:5033417; http://dx.doi.org/10.1084/jem.136.1.128
   PubMed Web of Science ®Google Scholar
• Smith KA, Gilbride KJ, Favata MF. Lymphocyte activating factor promotes T-cell growth factor production by cloned murine lymphoma cells. Nature 1980; 287:853-5; PMID:6776414; http://dx.doi.org/10.1038/287853a0
   PubMed Web of Science ®Google Scholar
• Smith KA, Lachman LB, Oppenheim JJ, Favata MF. The functional relationship of the interleukins. J Exp Med 1980; 151:1551-6; PMID:6770028; http://dx.doi.org/10.1084/jem.151.6.1551
   PubMed Web of Science ®Google Scholar
• Smith KA. Interleukin-2: inception, impact, and implications. Science 1988; 240:1169-76; PMID:3131876; http://dx.doi.org/10.1126/science.3131876
   PubMed Web of Science ®Google Scholar
• Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 2012; 12:180-90; PMID:22343569; http://dx.doi.org/10.1126/science.1122927
   PubMed Web of Science ®Google Scholar
• Gillis S. Interleukin 2: biology and biochemistry. J Clin Immunol 1983; 3:1-13; PMID:6338024; http://dx.doi.org/10.1007/BF00919133
   PubMed Web of Science ®Google Scholar
• Herberman RB. Natural killer cells. Annu Rev Med 1986; 37:347-52; PMID:3518610; http://dx.doi.org/10.1146/annurev.me.37.020186.002023
   PubMed Web of Science ®Google Scholar
• Choi YS. Differentiation and apoptosis of human germinal center B-lymphocytes. Immunol Res 1997; 16:161-74; PMID:9212362; http://dx.doi.org/10.1007/BF02786360
   PubMed Web of Science ®Google Scholar
• Oppenheim MH, Lotze MT. Interleukin-2: solid-tumor therapy. Oncology 1994; 51:154-69; PMID:8196899; http://dx.doi.org/10.1159/000227330
   PubMed Web of Science ®Google Scholar
• Somersalo K. Migratory functions of natural killer cells. Nat Immun 1996; 15:117-33; PMID:9162262
   PubMedGoogle Scholar
• Johnson JG, Jenkins MK. Co-stimulatory functions of antigen-presenting cells. J Invest Dermatol 1992; 99:62S-5S; PMID:1358981; http://dx.doi.org/10.1111/1523-1747.ep12669010
   PubMedGoogle Scholar
• Rothenberg EV, Ward SB. A dynamic assembly of diverse transcription factors integrates activation and cell-type information for interleukin 2 gene regulation. Proc Natl Acad Sci U S A 1996; 93:9358-65; PMID:8790334; http://dx.doi.org/10.1073/pnas.93.18.9358
   PubMed Web of Science ®Google Scholar
• Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992; 71:1065-8; PMID:1335362; http://dx.doi.org/10.1016/S0092-8674(05)80055-8
   PubMed Web of Science ®Google Scholar
• Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A 2006; 103:2788-93; PMID:16477002; http://dx.doi.org/10.1073/pnas.0511161103
   PubMed Web of Science ®Google Scholar
• Wang HM, Smith KA. The interleukin 2 receptor. Functional consequences of its bimolecular structure. J Exp Med 1987; 166:1055-69; PMID:3116143; http://dx.doi.org/10.1084/jem.166.4.1055
   PubMed Web of Science ®Google Scholar
• Nelson BH, Willerford DM. Biology of the interleukin-2 receptor. Adv Immunol 1998; 70:1-81; PMID:9755337; http://dx.doi.org/10.1016/S0065-2776(08)60386-7
   PubMed Web of Science ®Google Scholar
• Zhang X, Sun S, Hwang I, Tough DF, Sprent J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 1998; 8:591-9; PMID:9620680; http://dx.doi.org/10.1016/S1074-7613(00)80564-6
   PubMed Web of Science ®Google Scholar
• Brisslert M, Bokarewa M, Larsson P, Wing K, Collins LV, Tarkowski A. Phenotypic and functional characterization of human CD25+ B cells. Immunology 2006; 117:548-57; PMID:16556269; http://dx.doi.org/10.1111/j.1365-2567.2006.02331.x
   PubMed Web of Science ®Google Scholar
• Espinoza-Delgado I, Ortaldo JR, Winkler-Pickett R, Sugamura K, Varesio L, Longo DL. Expression and role of p75 interleukin 2 receptor on human monocytes. J Exp Med 1990; 171:1821-6; PMID:2110244; http://dx.doi.org/10.1084/jem.171.5.1821
   PubMed Web of Science ®Google Scholar
• Kronin V, Vremec D, Shortman K. Does the IL-2 receptor alpha chain induced on dendritic cells have a biological function? Int Immunol 1998; 10:237-40; PMID:9533452; http://dx.doi.org/10.1093/intimm/10.2.237
   PubMed Web of Science ®Google Scholar
• Hodge S, Hodge G, Flower R, Han P. Surface and intracellular interleukin-2 receptor expression on various resting and activated populations involved in cell-mediated immunity in human peripheral blood. Scand J Immunol 2000; 51:67-72; PMID:10632978; http://dx.doi.org/10.1046/j.1365-3083.2000.00644.x
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6:1142-51; PMID:16227984; http://dx.doi.org/10.1038/ni1263
   PubMed Web of Science ®Google Scholar
• Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004; 4:665-74; PMID:15343366; http://dx.doi.org/10.1038/nri1435
   PubMed Web of Science ®Google Scholar
• Comes A, Rosso O, Orengo AM, Di Carlo E, Sorrentino C, Meazza R, Piazza T, Valzasina B, Nanni P, Colombo MP et al. CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J Immunol 2006; 176:1750-8; PMID:16424205; http://dx.doi.org/10.4049/jimmunol.176.3.1750
   PubMed Web of Science ®Google Scholar
• Suvas S, Kumaraguru U, Pack CD, Lee S, Rouse BT. CD4+CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses. J Exp Med 2003; 198:889-901; PMID:12975455; http://dx.doi.org/10.1084/jem.20030171
   PubMed Web of Science ®Google Scholar
• Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T, Shimizu J, Nomura T, Chiba T, Sakaguchi S. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 2005; 202:885-91; PMID:16186187; http://dx.doi.org/10.1084/jem.20050940
   PubMed Web of Science ®Google Scholar
• Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22:531-62; PMID:15032588; http://dx.doi.org/10.1146/annurev.immunol.21.120601.141122
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol 2014; 192:5451-8; PMID:24907378; http://dx.doi.org/10.4049/jimmunol.1490019
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313:1485-92; PMID:3903508; http://dx.doi.org/10.1056/NEJM198512053132327
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316:889-97; PMID:3493432; http://dx.doi.org/10.1056/NEJM198704093161501
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271:907-13; PMID:8120958; http://dx.doi.org/10.1001/jama.1994.03510360033032
   PubMed Web of Science ®Google Scholar
• Griffith KD, Read EJ, Carrasquillo JA, Carter CS, Yang JC, Fisher B, Aebersold P, Packard BS, Yu MY, Rosenberg SA. In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J Natl Cancer Inst 1989; 81:1709-17; PMID:2810387; http://dx.doi.org/10.1093/jnci/81.22.1709
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994; 86:1159-66; PMID:8028037; http://dx.doi.org/10.1093/jnci/86.15.1159
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988; 319:1676-80; PMID:3264384; http://dx.doi.org/10.1056/NEJM198812223192527
   PubMed Web of Science ®Google Scholar
• Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 1987; 138:989-95; PMID:3100623
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-4; PMID:12242449; http://dx.doi.org/10.1126/science.1076514
   PubMed Web of Science ®Google Scholar
• Cooper DA, Emery S. Latent reservoirs of HIV infection: flushing with IL-2? Nat Med 1999; 5:611-2; PMID:10371491; http://dx.doi.org/10.1038/9454
   PubMed Web of Science ®Google Scholar
• Sereti I, Anthony KB, Martinez-Wilson H, Lempicki R, Adelsberger J, Metcalf JA, Hallahan CW, Follmann D, Davey RT, Kovacs JA et al. IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood 2004; 104:775-80; PMID:15090457; http://dx.doi.org/10.1182/blood-2003-12-4355
   PubMed Web of Science ®Google Scholar
• Group I-ES, Committee SS, Abrams D, Levy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361:1548-59; PMID:19828532; http://dx.doi.org/10.1056/NEJMoa0903175
   PubMed Web of Science ®Google Scholar
• Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, Squiban P. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci U S A 2004; 101 Suppl 2:14567-71; PMID:15333750; http://dx.doi.org/10.1073/pnas.0404845101
   PubMed Web of Science ®Google Scholar
• Parker SE, Khatibi S, Margalith M, Anderson D, Yankauckas M, Gromkowski SH, Latimer T, Lew D, Marquet M, Manthorpe M et al. Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo. Cancer Gene Ther 1996; 3:175-85; PMID:8725882
   PubMed Web of Science ®Google Scholar
• Melder RJ, Osborn BL, Riccobene T, Kanakaraj P, Wei P, Chen G, Stolow D, Halpern WG, Migone TS, Wang Q et al. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice. Cancer Immunol Immunother 2005; 54:535-47; PMID:15592670; http://dx.doi.org/10.1007/s00262-004-0624-7
   PubMed Web of Science ®Google Scholar
• Klimka A, Yu N, Shami EY. Construction of proteolysis resistant human interleukin-2 by fusion to its protective single chain antibody. Cytokine 2003; 22:134-41; PMID:12842761; http://dx.doi.org/10.1016/S1043-4666(03)00136-4
   PubMed Web of Science ®Google Scholar
• Barouch DH, Truitt DM, Letvin NL. Expression kinetics of the interleukin-2/immunoglobulin (IL-2/Ig) plasmid cytokine adjuvant. Vaccine 2004; 22:3092-7; PMID:15297060; http://dx.doi.org/10.1016/j.vaccine.2004.01.065
   PubMed Web of Science ®Google Scholar
• Katre NV, Knauf MJ, Laird WJ. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc Natl Acad Sci U S A 1987; 84:1487-91; PMID:3494243; http://dx.doi.org/10.1073/pnas.84.6.1487
   PubMed Web of Science ®Google Scholar
• Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006; 311:1924-7; PMID:16484453; http://dx.doi.org/10.1126/science.1122927
   PubMed Web of Science ®Google Scholar
• Ku CC, Murakami M, Sakamoto A, Kappler J, Marrack P. Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science 2000; 288:675-8; PMID:10784451; http://dx.doi.org/10.1126/science.288.5466.675
   PubMed Web of Science ®Google Scholar
• Murakami M, Sakamoto A, Bender J, Kappler J, Marrack P. CD25+CD4+ T cells contribute to the control of memory CD8+ T cells. Proc Natl Acad Sci U S A 2002; 99:8832-7; PMID:12084927; http://dx.doi.org/10.1073/pnas.132254399
   PubMed Web of Science ®Google Scholar
• Kamimura D, Ueda N, Sawa Y, Hachida S, Atsumi T, Nakagawa T, Sawa S, Jin GH, Suzuki H, Ishihara K et al. Evidence of a novel IL-2/15R β-targeted cytokine involved in homeostatic proliferation of memory CD8+ T cells. J Immunol 2004; 173:6041-9; PMID:15528339; http://dx.doi.org/10.4049/jimmunol.173.10.6041
   PubMed Web of Science ®Google Scholar
• Tomala J, Chmelova H, Mrkvan T, Rihova B, Kovar M. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy. J Immunol 2009; 183:4904-12; PMID:19801515; http://dx.doi.org/10.4049/jimmunol.0900284
   PubMed Web of Science ®Google Scholar
• Webster KE, Walters S, Kohler RE, Mrkvan T, Boyman O, Surh CD, Grey ST, Sprent J. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med 2009; 206:751-60; PMID:19332874; http://dx.doi.org/10.1084/jem.20082824
   PubMed Web of Science ®Google Scholar
• Finkelman FD, Madden KB, Morris SC, Holmes JM, Boiani N, Katona IM, Maliszewski CR. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol 1993; 151:1235-44; PMID:8393043
   PubMed Web of Science ®Google Scholar
• Jones AT, Ziltener HJ. Enhancement of the biologic effects of interleukin-3 in vivo by anti-interleukin-3 antibodies. Blood 1993; 82:1133-41; PMID:8353280
   PubMed Web of Science ®Google Scholar
• Heremans H, Dillen C, Put W, Van Damme J, Billiau A. Protective effect of anti-interleukin (IL)-6 antibody against endotoxin, associated with paradoxically increased IL-6 levels. Eur J Immunol 1992; 22:2395-401; PMID:1381315; http://dx.doi.org/10.1002/eji.1830220932
   PubMed Web of Science ®Google Scholar
• Martens E, Dillen C, Put W, Heremans H, van Damme J, Billiau A. Increased circulating interleukin-6 (IL-6) activity in endotoxin-challenged mice pretreated with anti-IL-6 antibody is due to IL-6 accumulated in antigen-antibody complexes. Eur J Immunol 1993; 23:2026-9; PMID:8344369; http://dx.doi.org/10.1002/eji.1830230846
   PubMed Web of Science ®Google Scholar
• Boyman O, Ramsey C, Kim DM, Sprent J, Surh CD. IL-7/anti-IL-7 mAb complexes restore T cell development and induce homeostatic T Cell expansion without lymphopenia. J Immunol 2008; 180:7265-75; PMID:18490726; http://dx.doi.org/10.4049/jimmunol.180.11.7265
   PubMed Web of Science ®Google Scholar
• Rubinstein MP, Salem ML, Doedens AL, Moore CJ, Chiuzan C, Rivell GL, Cole DJ, Goldrath AW. G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses. J Hematol Oncol 2013; 6:75; PMID:24279871; http://dx.doi.org/10.1186/1756-8722-6-75
   PubMed Web of Science ®Google Scholar
• Zabeau L, Van der Heyden J, Broekaert D, Verhee A, Vandekerckhove J, Wu SJ, Chaiken I, Heinrich P, Behrmann I, Tavernier J. Neutralizing monoclonal antibodies can potentiate IL-5 signaling. Eur J Immunol 2001; 31:1087-97; PMID:11298333; http://dx.doi.org/10.1002/1521-4141(200104)31:4%3c1087::AID-IMMU1087%3e3.0.CO;2-Q
   PubMed Web of Science ®Google Scholar
• Rosenblum MG, Unger BW, Gutterman JU, Hersh EM, David GS, Frincke JM. Modification of human leukocyte interferon pharmacology with a monoclonal antibody. Cancer Res 1985; 45:2421-4; PMID:3986783
   PubMed Web of Science ®Google Scholar
• Hamilton SE, Schenkel JM, Akue AD, Jameson SC. IL-2 complex treatment can protect naive mice from bacterial and viral infection. J Immunol 2010; 185:6584-90; PMID:21037095; http://dx.doi.org/10.4049/jimmunol.1001215
   PubMed Web of Science ®Google Scholar
• Kamimura D, Sawa Y, Sato M, Agung E, Hirano T, Murakami M. IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb. J Immunol 2006; 177:306-14; PMID:16785526; http://dx.doi.org/10.4049/jimmunol.177.1.306
   PubMed Web of Science ®Google Scholar
• Rojas G, Cabrera Infante Y, Pupo A, Carmenate T. Fine epitope specificity of antibodies against interleukin-2 explains their paradoxical immunomodulatory effects. MAbs 2014; 6:273-85; PMID:24253188; http://dx.doi.org/10.4161/mabs.27224
   PubMed Web of Science ®Google Scholar
• Tomala J, Chmelova H, Strohalm J, Ulbrich K, Sirova M, Rihova B, Kovar M. Antitumor activity of IL-2/anti-IL-2 mAb immunocomplexes exerts synergism with that of N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugate due to its low immunosuppressive activity. Int J Cancer 2011; 129:2002-12; PMID:21165950; http://dx.doi.org/10.1002/ijc.25859
   PubMed Web of Science ®Google Scholar
• Liu R, Zhou Q, La Cava A, Campagnolo DI, Van Kaer L, Shi FD. Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia. Eur J Immunol 2010; 40:1577-89; PMID:20352624; http://dx.doi.org/10.1002/eji.200939792
   PubMed Web of Science ®Google Scholar
• Kamimura D, Bevan MJ. Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo. J Exp Med 2007; 204:1803-12; PMID:17664293; http://dx.doi.org/10.1084/jem.20070543
   PubMed Web of Science ®Google Scholar
• Verdeil G, Marquardt K, Surh CD, Sherman LA. Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy. Proc Natl Acad Sci U S A 2008; 105:16683-8; PMID:18936481; http://dx.doi.org/10.1073/pnas.0805054105
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ. Biologic therapy with interleukin-2: clinical applications. Principles of administration and management of side effects. Philadelphia:Lippincott Williams & Wilkins, 1995.
   Google Scholar
• Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2. Oncology (Williston Park) 2002; 16:11-20; PMID:12469935
   PubMed Web of Science ®Google Scholar
• West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316:898-905; PMID:3493433; http://dx.doi.org/10.1056/NEJM198704093161502
   PubMed Web of Science ®Google Scholar
• Krieg C, Letourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A 2010; 107:11906-11; PMID:20547866; http://dx.doi.org/10.1073/pnas.1002569107
   PubMed Web of Science ®Google Scholar
• Epstein AL, Mizokami MM, Li J, Hu P, Khawli LA. Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst 2003; 95:741-9; PMID:12759392; http://dx.doi.org/10.1093/jnci/95.10.741
   PubMed Web of Science ®Google Scholar
• Letourneau S, van Leeuwen EM, Krieg C, Martin C, Pantaleo G, Sprent J, Surh CD, Boyman O. IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc Natl Acad Sci U S A 2010; 107:2171-6; PMID:20133862; http://dx.doi.org/10.1073/pnas.0909384107
   PubMed Web of Science ®Google Scholar
• Phelan JD, Orekov T, Finkelman FD. Cutting edge: mechanism of enhancement of in vivo cytokine effects by anti-cytokine monoclonal antibodies. J Immunol 2008; 180:44-8; PMID:18097002; http://dx.doi.org/10.4049/jimmunol.180.1.44
   PubMed Web of Science ®Google Scholar
• Rojas G, Pupo A, Leon K, Avellanet J, Carmenate T, Sidhu S. Deciphering the molecular bases of the biological effects of antibodies against Interleukin-2: a versatile platform for fine epitope mapping. Immunobiology 2013; 218:105-13; PMID:22459271; http://dx.doi.org/10.1016/j.imbio.2012.02.009
   PubMed Web of Science ®Google Scholar
• Tomala J, Kovarova J, Kabesova M, Votavova P, Chmelova H, Dvorakova B, Rihova B, Kovar M. Chimera of IL-2 linked to light chain of anti-IL-2 mAb mimics IL-2/anti-IL-2 mAb complexes both structurally and functionally. ACS Chem Biol 2013; 8:871-6; PMID:23419043; http://dx.doi.org/10.1021/cb3007242
   PubMed Web of Science ®Google Scholar
• Spangler JB, Tomala J, Luca VC, Jude KM, Dong S, Ring AM, Votavova P, Pepper M, Kovar M, Garcia KC. Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms. Immunity 2015; 42:815-25; PMID:25992858; http://dx.doi.org/10.1016/j.immuni.2015.04.015
   PubMed Web of Science ®Google Scholar
• Carmenate T, Pacios A, Enamorado M, Moreno E, Garcia-Martinez K, Fuente D, León K. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J Immunol 2013; 190:6230-8; PMID:23677467; http://dx.doi.org/10.4049/jimmunol.1201895
   PubMed Web of Science ®Google Scholar
• Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, Moraga I, Raeber ME, Bowman GR, Novick P et al. Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’. Nature 2012; 484:529-33; PMID:22446627; http://dx.doi.org/10.1038/nature10975
   PubMed Web of Science ®Google Scholar
• Molloy MJ, Zhang W, Usherwood EJ. Cutting edge: IL-2 immune complexes as a therapy for persistent virus infection. J Immunol 2009; 182:4512-5; PMID:19342623; http://dx.doi.org/10.4049/jimmunol.0804175
   PubMed Web of Science ®Google Scholar